Vinay Prasad has been reinstated to his role as the director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) less than two weeks after his resignation. Prasad oversees regulation of vaccines, gene therapies, and blood products. His abrupt departure in late July followed pressure from conservative allies of former President Donald Trump, biotech executives, and patient groups, amid allegations that he was too liberal and controversies surrounding a Duchenne gene therapy review. The reinstatement reportedly occurred at the behest of FDA official Marty Makary. Prasad's return has caused fluctuations in biotech stocks, with shares falling upon news of his comeback. Internal agency dynamics remain unclear, including staff notifications and leadership changes within CBER. Prasad's reinstatement has reignited discussions about the influence of pharmaceutical companies and public health policy at the FDA.